- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Vaxil Bio Ltd (2): Vaxil Bio 1,244,441-share private placement | 2 | Stockwatch | ||
| 04.12.25 | Vaxil Bio Ltd (2): Vaxil Bio closes $140,000 private placement | 1 | Stockwatch | ||
| 04.12.25 | Vaxil Bio completes $140,000 private placement, announces board changes | 3 | Investing.com | ||
| VAXIL BIO Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Vaxil Bio Ltd.: Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors | 1 | GlobeNewswire (USA) | ||
| 24.11.25 | Vaxil Bio revises private placement terms, seeks to raise $350,000 | 2 | Investing.com | ||
| 24.11.25 | Vaxil Bio Ltd.: Vaxil Announces Update on Non-Brokered Private Placement | 2 | GlobeNewswire (USA) | ||
| 30.10.25 | Vaxil Bio Ltd (2): Vaxil Bio arranges $350,000 private placement | 2 | Stockwatch | ||
| 29.10.25 | Vaxil Bio Ltd.: Vaxil Announces Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 06.05.25 | Vaxil Bio Ltd.: Share Consolidation | 373 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the following updates... ► Artikel lesen | |
| 03.04.25 | Vaxil Bio Ltd.: Vaxil: Management and Operational Update | 221 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States NESS-ZIONA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 44,300 | -0,17 % | Moderna stands as the best performing large-cap healthcare stock YTD | ||
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | -16,51 % | ADMA Biologics drops amid short report from Culper Research | ||
| QIAGEN | 34,465 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | +2,82 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | -2,33 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,570 | -3,05 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,66 | +0,05 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 72,98 | -7,81 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,060 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 12,330 | -0,56 % | Stifel reiterates Buy on Contineum stock, keeps $29 price target | ||
| EVOTEC | 4,119 | 0,00 % | Welche Aktie jetzt kaufen? Evotec, Nel und Lahontan Gold. | Was ist denn da bei Nel los? Innerhalb weniger Tage hat die einstige Wasserstoffhoffnung über 20 % an Wert gewonnen. Der kurzfristige Abwärtstrend wurde verlassen. Doch Analysten sehen keine Trendwende.... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,480 | +2,74 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ERASCA | 14,645 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| LENZ THERAPEUTICS | 9,010 | -18,09 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen |
VAXIL BIO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VAXIL BIO LTD finden Sie auf Wallstreet Online.